Publications by authors named "A M Iglesias Bolanos"
Background: Decisions regarding mode of delivery in the context of a prior cesarean birth is complicated because both trial of labor after cesarean and elective repeat cesarean birth have risks and benefits.
Purpose: The objective of this study was to understand the perspective of women and obstetricians in Coatepeque, Guatemala, to guide the development of a decision aid about mode of birth for women with a history of prior cesarean.
Methods: We conducted in-depth semi-structured interviews with obstetricians at Coatepeque Hospital and women at the Center for Human Development in the southwest Trifinio region of Guatemala in February 2020.
Objectives: This study assessed the use and perceptions of physician associates/assistants (PAs) and NPs at liver transplant centers and sought to determine their financial effect.
Methods: Leaders of liver transplant programs performing 25 or more transplants in 2020 were contacted to complete an 11-question survey about the role and effect of PAs and NPs in liver transplant. A single-center retrospective analysis compared length of stay (LOS) and readmission rates for primary liver transplants and simultaneous liver-kidney transplants before and after a dedicated PA team was established.
Objectives: Limited research exists on COVID-19 associated brain fog, and on the long-term cognitive and psychiatric sequelae in racially and ethnically diverse patients. We characterize the neuropsychological sequelae of post-acute COVID-19 in a diverse cohort and investigate whether COVID-19 clinical severity remains associated with brain fog and cognitive deficits approximately 2 years post infection.
Methods: A cross-sectional study of patients with a history of COVID-19 hospitalization (March-September 2020).
Article Synopsis
- Osimertinib targets and inhibits the epidermal growth factor receptor (EGFR) in cancer cells, leading to cell death and reduced tumors, making it a key treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
- The ADAURA study compared the effects of osimertinib to a placebo in patients with surgically removed early-stage (IB-IIIA) EGFR-mutated NSCLC, showing that those on osimertinib had longer disease-free survival.
- Recent results reveal that osimertinib significantly improves overall survival, with a 51% lower risk of death for patients treated with it compared to the placebo group.
Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus placebo in resected stage IB to IIIA EGFRm NSCLC. We present efficacy and safety data from a subgroup analysis of 159 Chinese patients enrolled in the People's Republic of China from ADAURA.
View Article and Find Full Text PDF